---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-005707"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T14:08:31.327376+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OPKO Health Q4 revenue $181.9M; net loss narrows to $0.09/sh; $230M convertible notes issued

## Summary
- Consolidated revenue $181.9M vs $185.4M in prior-year quarter; net loss $65.5M ($0.09/sh) vs $85.2M ($0.11/sh).
- Diagnostics segment revenue fell 11% to $124.2M on lower reimbursement and COVID-19 testing decline.
- Pharmaceuticals revenue rose to $43.0M, driven by international operations and RAYALDEE sales of $9.3M.
- After quarter end, OPKO sold $230M of 3.75% convertible senior notes due 2029 and used $50M to repurchase stock.
- BioReference Health REACH program reduced annualized expenses by $10.1M; operating loss $42.3M including $4.7M non-recurring.

## SEC filing metadata
- accession: 0001437749-24-005707
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774924005707/0001437749-24-005707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774924005707/opk20240226_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-005707
- JSON: https://secwatch.observer/filing/0001437749-24-005707.json
- Plain text: https://secwatch.observer/filing/0001437749-24-005707.txt

## Key facts
- Earnings Releases
  OPKO HEALTH, INC. reported three and 12 months ended December 31, 2023 results: revenue $181.9 million, net income Net loss for the fourth quarter of 2023 was $65.5 million, or $0.09 per share, EPS $0.09 per share.
  - Period: three and 12 months ended December 31, 2023
  - Revenue: $181.9 million
  - Net income: Net loss for the fourth quarter of 2023 was $65.5 million, or $0.09 per share
  - EPS: $0.09 per share
  - Result: reported results
  source text: of revenue adjustments, compared with an operating loss of $23.1 million in the 2022 period. ● Consolidated: Consolidated total revenues for the fourth quarter of 2023 were $181.9 million compared with $185.4 million for the comparable 2022 period. Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for
  evidence_url: https://www.sec.gov/Archives/edgar/data/944809/000143774924005707/0001437749-24-005707-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.